Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19328055 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | September 2025 | December 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19310812 | REVERSE TRANSCRIPTASE VARIANTS | August 2025 | November 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19212289 | STABILIZATION OF TRYPTAMINES BY DENATURING ENZYMES, OPTIMIZING IONIZATION STATES, AND CONTROLLING CONFOUNDING VARIABLES | May 2025 | August 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 18984162 | CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATION | December 2024 | May 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18870088 | METHOD FOR PRODUCING GUANIDINO ACETIC ACID (GAA) | November 2024 | February 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18948388 | COMPOSITION COMPRISING COLLAGENASE, CALCIUM, HISTIDINE, AND GLYCINE, AND METHOD FOR STABILIZING COLLAGENASE | November 2024 | October 2025 | Allow | 11 | 2 | 0 | No | No |
| 18824681 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | September 2024 | November 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18648209 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | April 2024 | August 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18625448 | ALDEHYDE DEHYDROGENASE PRODUCING BACTERIA AND METHODS OF USING SAME | April 2024 | July 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18602534 | GENETICALLY MODIFIED PROBIOTICS FOR ORAL DELIVERY OF RENIN-ANGIOTENSIN RELATED THERAPEUTIC PROTEINS AND PEPTIDES | March 2024 | February 2026 | Allow | 23 | 0 | 0 | Yes | No |
| 18598286 | SYSTEMS FOR DETERMINING ADAMTS13 ENZYME ACTIVITY | March 2024 | June 2025 | Allow | 15 | 0 | 1 | Yes | No |
| 18595600 | ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | March 2024 | May 2025 | Allow | 14 | 0 | 1 | Yes | No |
| 18586709 | Polypeptides having Peptidoglycan Degrading Activity and Polynucleotides Encoding Same | February 2024 | January 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18432505 | MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERY | February 2024 | March 2025 | Allow | 13 | 0 | 0 | Yes | No |
| 18431554 | ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) | February 2024 | September 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18431662 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | February 2024 | February 2025 | Allow | 13 | 0 | 0 | Yes | No |
| 18424952 | MODIFIED IMMUNE CELLS HAVING ENHANCED FUNCTION AND METHODS FOR SCREENING THE SAME | January 2024 | January 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18416843 | ICAM-1 TARGETED FUSION ENZYMES | January 2024 | February 2025 | Allow | 13 | 0 | 0 | Yes | No |
| 18410876 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | January 2024 | March 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18410949 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | January 2024 | April 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18409535 | TREATMENT OF ABNORMAL BONE CONDITIONS IN ACID SPHINGOMYELINASE DEFICIENCY PATIENTS | January 2024 | January 2026 | Abandon | 24 | 2 | 0 | Yes | No |
| 18405674 | VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS | January 2024 | February 2025 | Allow | 13 | 0 | 0 | Yes | No |
| 18390884 | MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERY | December 2023 | May 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18525460 | HUMANIZED CELL LINE | November 2023 | October 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18502499 | CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATION | November 2023 | September 2024 | Allow | 10 | 0 | 0 | No | No |
| 18386621 | Mutant Taq Polymerase Providing Faster Amplification | November 2023 | February 2025 | Allow | 15 | 0 | 0 | Yes | No |
| 18379079 | Biological Production of Multi-Carbon Compounds from Methane | October 2023 | December 2025 | Allow | 26 | 1 | 0 | Yes | No |
| 18483460 | PROGRAMMED DNA-DRIVEN SELF-ASSEMBLED RNA HYDROGEL | October 2023 | September 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18483386 | PROGRAMMED DNA-DRIVEN SELF-ASSEMBLED RNA HYDROGEL | October 2023 | November 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18472540 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE | September 2023 | August 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18454701 | COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA | August 2023 | September 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18450994 | NUCLEIC ACID ENCODING MODIFIED MEMBRANE TYPE SERINE PROTEASE 1 (MTSP-1) POLYPEPTIDES AND METHODS OF USE | August 2023 | August 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18357617 | Compositions and Methods for Treating Celiac Sprue Disease | July 2023 | January 2025 | Allow | 18 | 0 | 0 | Yes | No |
| 18355990 | ACYL-ACP Reductase With Improved Properties | July 2023 | August 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18351198 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION | July 2023 | December 2024 | Allow | 17 | 0 | 0 | Yes | No |
| 18345783 | METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITS | June 2023 | August 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18340083 | FCE MRNA CAPPING ENZYME COMPOSITIONS, METHODS AND KITS | June 2023 | July 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18333344 | METHODS AND COMPOSITIONS FOR IN VIVO GENE EDITING BASED CELL-TYPE-SPECIFIC CELLULAR ENGINEERING | June 2023 | July 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18208272 | COMPOSITIONS OF MATTER FOR DETECTION ASSAYS | June 2023 | October 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18265002 | ENGINEERED MICROORGANISMS | June 2023 | March 2026 | Allow | 34 | 0 | 0 | Yes | No |
| 18204337 | COMPOSITIONS OF MATTER FOR DETECTION ASSAYS | May 2023 | September 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18316880 | SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA | May 2023 | November 2024 | Allow | 19 | 0 | 0 | Yes | No |
| 18313955 | PROCESS OF EXTRACTING OIL FROM THIN STILLAGE | May 2023 | August 2024 | Allow | 15 | 0 | 0 | Yes | No |
| 18251712 | MACROPINOCYTOSIS SELECTIVE MONOBODY-DRUG CONJUGATES | May 2023 | January 2026 | Allow | 33 | 0 | 0 | Yes | No |
| 18310448 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | May 2023 | December 2023 | Allow | 7 | 0 | 1 | Yes | No |
| 18139481 | PLATFORM FOR EXPRESSING PROTEIN OF INTEREST IN LIVER | April 2023 | June 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18304286 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | April 2023 | March 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18032999 | COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES FOR TREATING MYELOPROLIFERATIVE NEOPLASMS | April 2023 | February 2026 | Allow | 33 | 0 | 0 | Yes | No |
| 18301790 | PROCESSES FOR THE PRODUCTION OF TRYPTAMINES | April 2023 | December 2025 | Allow | 32 | 1 | 1 | Yes | No |
| 18130300 | GENOME EDITING METHOD | April 2023 | July 2024 | Allow | 16 | 0 | 0 | Yes | No |
| 18194471 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | March 2023 | June 2024 | Allow | 15 | 0 | 0 | Yes | No |
| 18193002 | BRIGHT AND STABLE RED FLUORESCENT PROTEIN | March 2023 | January 2026 | Allow | 34 | 0 | 0 | Yes | No |
| 18187102 | Compositions and methods for improved malonyl-CoA biosynthesis using 2-stage dynamic metabolic control | March 2023 | April 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18185726 | RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES | March 2023 | March 2025 | Allow | 24 | 0 | 1 | Yes | No |
| 18178048 | METHODS AND COMPOSITIONS FOR EVOLVING BASE EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) | March 2023 | March 2025 | Allow | 24 | 0 | 1 | Yes | No |
| 18177672 | SARS-CoV-2 Vaccines and Antibodies | March 2023 | December 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 18023891 | SINGLE-CHAIN CORONAVIRUS VIRAL MEMBRANE PROTEIN COMPLEXES | February 2023 | December 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 18170045 | IN VITRO GLYCOSYLATION OF PROTEINS AND ENZYMES | February 2023 | May 2024 | Allow | 15 | 0 | 0 | Yes | No |
| 18021270 | ENGINEERED POLYMERASES AND METHODS OF USING THE SAME | February 2023 | August 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18167119 | STEVIOL GLYCOSIDE TRANSPORT | February 2023 | May 2024 | Allow | 15 | 0 | 0 | Yes | No |
| 17764925 | MNEP MONOMER VARIANT AND APPLICATION THEREOF | February 2023 | August 2025 | Allow | 41 | 0 | 0 | Yes | No |
| 18106420 | COMPOSITIONS OF MATTER FOR DETECTION ASSAYS | February 2023 | May 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18160947 | ENGINEERED POLYMERASES WITH REDUCED SEQUENCE-SPECIFIC ERRORS | January 2023 | June 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18016440 | IMMUNOGLOBULIN BINDING PROTEINS FOR AFFINITY PURIFICATION | January 2023 | November 2025 | Allow | 34 | 0 | 1 | Yes | No |
| 18089023 | SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMS | December 2022 | December 2024 | Allow | 24 | 0 | 0 | Yes | No |
| 18011785 | PRO-MICROBIAL SURFACE | December 2022 | August 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 18058823 | MODIFIED CAS9 PROTEIN, AND USE THEREOF | November 2022 | July 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 18058703 | THERAPEUTICS AND POINT OF CARE LATERAL-FLOW TEST FOR VIRUS AND ANTIBODIES USING TAGGED ASSEMBLED PROTEINS | November 2022 | September 2023 | Allow | 10 | 0 | 1 | Yes | No |
| 17927337 | METHODS AND COMPOSITIONS TO SPREAD PROTEIN CARGOES ACROSS MULTI-NUCLEATED CELLS | November 2022 | February 2026 | Allow | 39 | 0 | 1 | Yes | No |
| 17999260 | COMPOSITIONS AND METHODS FOR DNA CYTOSINE CARBOXYMETHYLATION | November 2022 | February 2026 | Allow | 39 | 0 | 1 | Yes | No |
| 18055718 | SYSTEMS, METHODS, AND COMPOSITIONS FOR CORRECTION OF FRAMESHIFT MUTATIONS | November 2022 | July 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 17998543 | EMID2 PROTEIN AS ANTI-CANCER TREATMENT | November 2022 | February 2026 | Abandon | 39 | 1 | 0 | Yes | No |
| 17924177 | STRUCTURALLY MODIFIED CHIMERIC POLYPEPTIDE OF HUMAN PAPILLOMAVIRUS, RECOMBINANT PROTEIN COMPRISING SAME POLYPEPTIDE, AND USE OF SAME PROTEIN | November 2022 | July 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 18052519 | METHODS AND COMPOSITIONS FOR MAKING BACTERIOCINS AND ANTIMICROBIAL PEPTIDES | November 2022 | May 2024 | Allow | 18 | 0 | 0 | Yes | No |
| 18048548 | Compositions, Methods, and Applications of a Synthetic Surfactant | October 2022 | August 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17920410 | HIGHLY ALKALINE TEXTILE DETERGENT COMPRISING PROTEASE | October 2022 | July 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17920407 | HIGHLY ALKALINE TEXTILE WASHING AGENT COMPRISING PROTEASE | October 2022 | July 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 18047589 | MODIFIED HELICASES | October 2022 | November 2024 | Allow | 25 | 0 | 1 | Yes | No |
| 18047019 | MODIFIED HELICASES | October 2022 | November 2024 | Allow | 25 | 0 | 1 | Yes | No |
| 17765921 | TISSUE ADHESION COMPOSITION WITH BIO-TISSUE ADHESIVENESS AND BONDING FORCE AND PREPARATION METHOD THEREFOR | October 2022 | January 2026 | Abandon | 46 | 0 | 1 | No | No |
| 17918835 | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF | October 2022 | November 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17995794 | GALECTIN-1 IMMUNOMODULATION AND MYOGENIC IMPROVEMENTS IN MUSCLE DISEASES AND AUTOIMMUINE DISORDERS | October 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17960210 | GENE KNOCKOUT OF VARIANT NRF2 FOR TREATMENT OF CANCER | October 2022 | March 2024 | Allow | 17 | 0 | 0 | No | No |
| 17960224 | GENE KNOCKOUT OF VARIANT NRF2 FOR TREATMENT OF CANCER | October 2022 | March 2024 | Allow | 17 | 0 | 0 | No | No |
| 17959089 | MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS | October 2022 | June 2025 | Allow | 32 | 1 | 1 | Yes | No |
| 17931352 | Enzyme Based System for Production of Messenger RNA with Increased Transfection Efficiency | September 2022 | July 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17943127 | Flp-TAL RECOMBINASES | September 2022 | February 2024 | Allow | 17 | 0 | 0 | Yes | No |
| 17940797 | REVERSE TRANSCRIPTASE VARIANTS | September 2022 | December 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17930626 | COMPOSITIONS OF ANTI-VIRAL PEPTIDES AND METHODS OF USE THEREOF | September 2022 | June 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17802018 | CHIMERIC RECEPTORS FOR USE IN ENGINEERED CELLS | August 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17893530 | ORGANELLE-TARGETED GENETICALLY-ENCODED VOLTAGE INDICATORS AND METHODS OF USE THEREOF | August 2022 | July 2023 | Allow | 11 | 0 | 0 | Yes | No |
| 17798524 | EXOSOME COMPRISING PHOTOCLEAVABLE PROTEIN, AND USE THEREOF | August 2022 | May 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17878657 | Recombinant expression platform, constructs and methods for expression of Difficult to Express Proteins (DTE-Ps) | August 2022 | October 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17815453 | RNA-GUIDED NUCLEASES AND DNA BINDING PROTEINS | July 2022 | April 2024 | Allow | 21 | 0 | 0 | Yes | No |
| 17814972 | LONG CHAIN DIBASIC ACID WITH LOW CONTENT OF LONG CHAIN DIBASIC ACID IMPURITY OF SHORTER CARBON-CHAIN AND PREPARATION METHOD THEREOF | July 2022 | February 2024 | Allow | 19 | 0 | 0 | Yes | No |
| 17870336 | DNase H Activity of Neisseria Meningitidis Cas9 | July 2022 | May 2024 | Allow | 22 | 0 | 0 | No | No |
| 17758959 | ANTI-DINITROPHENOL CHIMERIC ANTIGEN RECEPTORS | July 2022 | November 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17812712 | CHIMERIC POLYPEPTIDES | July 2022 | June 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17812400 | RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOF | July 2022 | June 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17812182 | LACTOBACILLUS PARACASEI TCI727 AND METHOD FOR PROMOTING CALCIUM ABSORPTION BY USING LACTOBACILLUS PARACASEI TCI727/OR ITS METABOLITES | July 2022 | January 2024 | Allow | 18 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, JAE W.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEE, JAE W works in Art Unit 1656 and has examined 962 patent applications in our dataset. With an allowance rate of 74.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 28 months.
Examiner LEE, JAE W's allowance rate of 74.9% places them in the 40% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by LEE, JAE W receive 0.96 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by LEE, JAE W is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +60.6% benefit to allowance rate for applications examined by LEE, JAE W. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 29.9% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 27.0% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 86.7% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 84.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 51.6% are granted (fully or in part). This grant rate is in the 51% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 10.3% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.